Primary squamous cell carcinoma of the rectum: An update and implications for treatment

Table 2 Chemoradiation as primary treatment of rectal squamous cell carcinoma

Ref.	Pts	Chemotherapy		RTx (Gy)	CR	Surgery	Path CR	Recurrence	Survival(ANED)	Follow up(mo)
		5FU/MMC	Other
Vezeridis et al[25]	1	-	1	40	-	-	-	LR - 1	0%	15
1Schneider et al[70]	1	1	-	30	-	-	-	-	NR	-
Kulayat et al[13]	1	1	-	40	-	TPC	100%	-	100% (1)	48
Martinez-Gonzalez et al[75]	1	-	1	46	-	AR	0%	-	100% (1)	18
Gelas et al[69]	2	-	2	Y	-	AR - 2	0%	-	100 % (2)	6-24
Theodosopoulos et al[98]	1	1	-	20	-	APR	0%	M - 1	100% (1)	18
Pikarsky et al[9]	1	1	-	60	1	-	-	-	100% (1)	84
Nahas et al[16]	9	6	3	50.4	2	TAE - 2 APR - 2 AR - 3	86%	-	100% (9)	6-192
Clark et al[61]	7	3	4	50.4	7	AR - 1	100%	-	100% (7)	5-31
Matsuda et al[29]	1	-	1	59.4	-	APR	0%	LR - 1, M - 1	0%	24
Brammer et al[99]	1	1	-	Y	1	-	-	M - 1	100% (1)	24
Rasheed et al[57]	6	2	4	45-50.4	4	APR - 2	50%	LR - 1	100% (6)	2-132
Al Hallak et al[100]	1	1	-	Y	1	-	-	-	100% (1)	30
Tronconi et al[58]	6	1	5	50.4-59.4	4	AR - 1 H - 1	50%	M - 1	83% (5)	24-41
Iannacone et al[101]	1	1	-	59.4	1	-	-	-	100% (1)	12
Wang et al[60]	5	5	-	45-54	4	AR - 2 APR - 1	100%	M - 2	60% (3)	15-51
Yeh et al[49]	5	4	1	30-60	4	AR - 1	100%	LR + M - 1	80% (4)	24-84
Jeong et al[62]	4	-	4	50.4-63	4	-	-	-	75% (3)	2-99
Kassir et al[102]	1	-	1	Y	-	AR	0%	-	100% (1)	-
Ferreira et al[64]	1	1	-	52	1	-	-	-	100% (1)	40
Choi et al[42]	1	1	-	Y	1	APR	0%	LR - 1	100% (1)	17
Musio et al[63]	8	6	2	45-70.6	4	APR - 4	50%	LR - 1	88% ( 7)	1-164
Péron et al[59]	10	4	6	45-62	6	APR - 2 AR - 2	50%	LR - 1	100% (10)	6-133
Funahashi et al[76]	3	-	3	45-59.4	2	PE	100%	M - 1	67% (2)	14-44
Seshadri et al[103]	1	1	-	50.4	1	AR	0%	LR + M - 1	0%	36
Ozuner et al[14]	1	1	-	Y	-	-	0%	M - 1	0%	12-96
Overall	79 (801)	42	38	All	60% (48)	44% (35)	57% (20)	LR 10% (8) M 13% (10)	86% (68)	1-192

¹Not included in analysis as no relevant information recorded. Pts: Number of patients in study; RTx: Radiotherapy; CR: Complete response; Path CR: Pathological complete response; ANED: Alive, no evidence of disease; Other: 5FU - 3, 5FU/Cisplatin - 26, Capecitabine/Cisplatin - 3; Capecitabine - 1; Raltitrexed/Oxaliplatin - 2; S1 - 3; Gy: Gray; AR: Anterior resection; H: Hartmann’s; PE: Pelvic exenteration; TAE: Trans-anal excision; TPC: Total proctocolectomy; APR: Abdominoperineal resection; NR: Not recorded; M: Metastasis; LR: Local recurrence.